WHO Launches Experimental Ebola Study Amid Congo Outbreak
The World Health Organization (WHO) has launched an experimental Ebola study in Congo in response to a rapidly spreading outbreak of the Bundibugyo strain of the virus. As of now, there are over 1,400 diagnosed cases and 438 deaths.
The WHO's study aims to evaluate the effectiveness of two test drugs: an antiviral drug called remdesivir and a new antibody mixture, or a combination of both. Patients will be monitored for 28 days post-treatment to assess survival rates.
The situation in Bunia is dire, with constant ambulance arrivals and medical staff required to wear heavy protective gear. The first patient has already received the test medicine, and health workers are urgently treating others to prevent further spread.
The WHO's intervention comes after significant loss of life, highlighting the need for improved global health crisis management, particularly in poorer nations. The data collected from this trial could lead to the first official treatment for this rare Ebola strain.
Plus234Feed summary based on reporting from Federal Character. Read the original report below.
Read full article
Continue on Federal Character
Get the week in one email
Top stories, NPFL results, the naira, every Friday morning. Free, one email a week.
Related Stories
WHO Launches Vaccine Trial Amid Ebola Outbreak in DRC
DR Congo Launches Ebola Prevention Drug Trial
WHO Allocates 20,000 Ervebo Doses for Ebola Trial
DRC Ebola Outbreak Uncontrolled, WHO Reports High Risk
WHO Calls for 5,000 Health Workers to Combat Ebola in DRC
WHO Rejects Ervebo Vaccine Rollout for Ebola Strain
Get Plus234Feed on messaging apps
Same headlines, delivered where you already scroll.
